摘要：目的 建立并评价新型冠状病毒特异性抗体定量检测方法，为新冠疫情防控提供血清学研判支持。方法 采集2020年1至2月间新冠病毒感染者及其密切接触者的血清和咽拭子样本，分别用RT-qPCR法检测新冠病毒核酸、微流控法和胶体金法检测新冠病毒特异性抗体，并比较分析两类结果的一致性。结果 微流控法、胶体金法检测新冠病毒特异性抗体IgG抗体均与RT-qPCR检测方法一致。发病早中期（<14天）与后期（≥14天）IgG抗体阳性率差异有统计学意义。结论 微流控法是一种新型可定量的新冠抗体检测法，检测结果准确且耗时短。本研究初步验证适用于检测新冠抗体，结论有待更多实验论证。
Abstract：Objective To establish and evaluate antibody quantitative detection methods of COVID-19 (Corona Virus Disease 2019), in order to provide serological data base for COVID-19 detection and prevention. Methods Between January and February 2020, to gather serum and pharyngeal swab samples of COVID-19 patients and their close contacts, then to test sera using Microfluidic and colloidal gold methods and nucleic acid using RT-qPCR (reverse transcription-quantitative Real-time PCR) respectively. Finally, the consistency of two sorts of results were analyzed and compared. Results There was no significant difference between the IgG (immunoglobulin G) antibody positive rates of Microfluidic method, colloidal gold method and the positive rates of RT-qPCR, but significant differences in IgG positive rates between the early-middle and the late stages by the Microfluidic method was noted. Conclusion As a novel quantitative way to detect COVID-19 antibodies, the microfluidic method is brief and accurate. Preliminarily verified by this study, this method is applied to quantify COVID-19 antibodies. For more practical applications, it requires more researches to confirm.